These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17667928)

  • 1. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.
    Schmidt J; Welsch T; Jäger D; Mühlradt PF; Büchler MW; Märten A
    Br J Cancer; 2007 Sep; 97(5):598-604. PubMed ID: 17667928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
    Schneider C; Schmidt T; Ziske C; Tiemann K; Lee KM; Uhlinsky V; Behrens P; Sauerbruch T; Schmidt-Wolf IG; Mühlradt PF; Schmidt J; Märten A
    Gut; 2004 Mar; 53(3):355-61. PubMed ID: 14960515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 2/6 agonist macrophage-activating lipopeptide-2 promotes reendothelialization and inhibits neointima formation after vascular injury.
    Grote K; Sonnenschein K; Kapopara PR; Hillmer A; Grothusen C; Salguero G; Kotlarz D; Schuett H; Bavendiek U; Schieffer B
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2097-104. PubMed ID: 23868938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.
    Müller C; Tufa DM; Chatterjee D; Mühlradt PF; Schmidt RE; Jacobs R
    Cancer Immunol Immunother; 2015 Sep; 64(9):1175-84. PubMed ID: 26036909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lung.
    Schill T; Schön MP; Pletz N; Emmert S; Schön M
    Exp Dermatol; 2012 Feb; 21(2):91-8. PubMed ID: 22044500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage-activating lipopeptide-2 (MALP-2) induces a localized inflammatory response in rats resulting in activation of brain sites implicated in fever.
    Knorr C; Hübschle T; Murgott J; Mühlradt P; Gerstberger R; Roth J
    Brain Res; 2008 Apr; 1205():36-46. PubMed ID: 18353287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrexia, anorexia, adipsia, and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and -6 agonists MALP-2 and FSL-1.
    Hübschle T; Mütze J; Mühlradt PF; Korte S; Gerstberger R; Roth J
    Am J Physiol Regul Integr Comp Physiol; 2006 Jan; 290(1):R180-7. PubMed ID: 16154916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of TLR-2/6 ligation in pulmonary bacterial infection and immunization with Pseudomonas aeruginosa.
    Kerber-Momot T; Leemhuis D; Lührmann A; Munder A; Tümmler B; Pabst R; Tschernig T
    Inflammation; 2010 Feb; 33(1):58-64. PubMed ID: 19844782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
    Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
    J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2.
    Sawahata R; Shime H; Yamazaki S; Inoue N; Akazawa T; Fujimoto Y; Fukase K; Matsumoto M; Seya T
    Microbes Infect; 2011 Apr; 13(4):350-8. PubMed ID: 21172450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local pulmonary immune stimulation by the Toll-like receptor 2 and 6 ligand MALP-2 in rats is age dependent.
    Lührmann A; Grote K; Stephan M; Tschernig T; Pabst R
    Immunol Lett; 2007 Feb; 108(2):167-73. PubMed ID: 17275100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
    Davis M; Conlon K; Bohac GC; Barcenas J; Leslie W; Watkins L; Lamzabi I; Deng Y; Li Y; Plate JM
    J Immunother; 2012 Oct; 35(8):629-40. PubMed ID: 22996369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
    Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct stimulatory effects of the TLR2/6 ligand bacterial lipopeptide MALP-2 on neutrophil granulocytes.
    Wilde I; Lotz S; Engelmann D; Starke A; van Zandbergen G; Solbach W; Laskay T
    Med Microbiol Immunol; 2007 Jun; 196(2):61-71. PubMed ID: 17006695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
    Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
    Okada KI; Shimokawa T; Hirono S; Kawai M; Sho M; Satoi S; Matsumoto I; Eguchi H; Murakami Y; Yamada S; Doi M; Yamaue H;
    Oncology; 2017; 93(5):343-346. PubMed ID: 28719890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
    Spry N; Harvey J; Macleod C; Borg M; Ngan SY; Millar JL; Graham P; Zissiadis Y; Kneebone A; Carroll S; Davies T; Reece WH; Iacopetta B; Goldstein D
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1438-46. PubMed ID: 18164859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
    Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
    Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.